Soleno Therapeutics (NASDAQ: SLNO) shares prelim 2025 results update

Rhea-AI Filing Summary

Soleno Therapeutics, Inc. filed a Form 8-K to report that it issued a press release announcing certain preliminary financial results and operating metrics for the three months and year ended December 31, 2025. The press release is furnished as Exhibit 99.1 and incorporated by reference.

The information is furnished under the results of operations and financial condition disclosure items and is explicitly stated as "furnished" rather than "filed," which limits how it is treated under securities law and in other future SEC filings.

SOLENO THERAPEUTICS INC false 0001484565 0001484565 2026-01-12 2026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): January 12, 2026

SOLENO THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-36593		77-0523891
(State or other jurisdiction of incorporation)		(Commission File No.)		(IRS Employer Identification Number)

100 Marine Parkway, Suite 400

Redwood City, CA 94065

(Address of principal executive offices)

(650) 213-8444

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbols		Name of each exchange on which registered
Common Stock, $0.001 par value		SLNO		NASDAQ

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

ITEM 2.02 Results of Operations and Financial Conditions

On January 12, 2026, Soleno Therapeutics, Inc. (the “Company”) issued a press release to announce certain preliminary financial results and operating metrics for the three months and year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

This information is intended to be furnished under Item 2.02 and Item 9.01 of Form 8-K, “Results of Operations and Financial Condition” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

ITEM 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.		Description
99.1		Press release issued by Soleno Therapeutics, Inc. dated January 12, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				SOLENO THERAPEUTICS, INC.
Date: January 12, 2026
				By:		/s/ Anish Bhatnagar
						Anish Bhatnagar
						Chief Executive Officer

FAQ

What did Soleno Therapeutics (SLNO) disclose in this Form 8-K?

Soleno Therapeutics reported that it issued a press release announcing certain preliminary financial results and operating metrics for the three months and year ended December 31, 2025, and furnished that release as an exhibit.

Which period do the preliminary results for Soleno Therapeutics (SLNO) cover?

The preliminary financial results and operating metrics relate to the three months and the full year ended December 31, 2025.

How did Soleno Therapeutics provide the preliminary results information to investors?

The company issued a press release and furnished it as Exhibit 99.1 to the Form 8-K, incorporating it by reference into the report.

Is the Soleno Therapeutics preliminary results information considered "filed" with the SEC?

No. The company states that the information is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section.

Which items of Form 8-K does Soleno Therapeutics use for this disclosure?

The information is intended to be furnished under the item relating to results of operations and financial condition, along with the financial statement and exhibit item.

Who signed the Soleno Therapeutics Form 8-K related to the preliminary results?

The report was signed on behalf of Soleno Therapeutics, Inc. by Anish Bhatnagar, the company’s Chief Executive Officer.